Lindsay Bealor Greenleaf discusses recent administrative actions related to drug pricing with Managed Healthcare Executive
Healthcare executives should view American Patients First—The Trump Administration Blueprint to lower dug prices and reduce out-of-pocket costs—as well as the subsequent flurry of drug pricing administrative actions across Medicare Part B and Part D, as a “clear sign that the Administration is serious about pursuing significant policy changes across payers,” according to Lindsay Bealor Greenleaf, director at healthcare advisory firm ADVI Health.
[el-text]
Written by Tracey Walker
***excerpt***
Healthcare executives should view American Patients First—The Trump Administration Blueprint to lower dug prices and reduce out-of-pocket costs—as well as the subsequent flurry of drug pricing administrative actions across Medicare Part B and Part D, as a “clear sign that the Administration is serious about pursuing significant policy changes across payers,” according to Lindsay Bealor Greenleaf, director at healthcare advisory firm ADVI Health.
***end excerpt***
***
[/el-text]
View full article here
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.